PIH15 COST EFFECTIVENESS ANALYSIS OF GOSERELIN EMPIRIC THERAPY FOR DEEP ENDOMETRIOSIS TREATMENT

Dejka M. Araujo, RBF Passos, CPR Souza, AP Silva, Mariana Florêncio Marques
In: Value in Health · 2009 · vol. 12(3) , pp. A164 · doi:10.1016/s1098-3015(10)73883-3 · W2043397345
article OA: closed CC0 ⤵ 1 in-corpus citation
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06, 2026-06-28 ⓘ

Goserelin empiric therapy for deep endometriosis is cost-effective, with higher costs in the first year but lower overall costs and better quality-adjusted life years over three years compared to standard care.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK